1. Aas T, Borresen A-L, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811–814
2. Adnane J, Gaudray P, Simon MP, Simony Lafontaine J, Jeanteur P, Theillet C (1989) Protooncogene amplification and human breast tumor phenotype. Oncogene 4: 1389–1395
3. Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T (1991) The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol 11: 833–842
4. Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M (1995) Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55: 3976–3981
5. Alle KM, Henshall SM, Field AS, Sutherland RL (1998) Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 4: 847–854